Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years

From Week 16-104, among IGA (0,1) responders at Week 16, increased proportions of patients achieved IGA (0) with lebrikizumab Q2W (33.8% [Nx = 77] to 52.3% [Nx = 44]) and Q4W (29.9% [Nx = 77] to 45.5% [Nx = 55]); among EASI 75 responders at Week 16, increased proportions of patients achieved EASI 100 with lebrikizumab Q2W (21.4% [Nx = 112] to 39.7% [Nx = 68]) and Q4W (20.0% [Nx = 115] to 41.3% [Nx = 80]); and among per-protocol responders, increased proportions of patients reported Pruritus NRS (0,1) with lebrikizumab Q2W (35.2% [Nx = 108] to 57.4% [Nx = 61]) and Q4W (34.2% [Nx = 114] to 55.4% [Nx = 65]). Continued lebrikizumab treatment for 2 years resulted in approximately half of per-protocol responders achieving complete skin clearance (IGA 0) and itch relief, raising the bar of treatment goals for AD patients.